| Patient | Pablo Neruda |
|---|---|
| Date of birth | 1904-07-12 |
| Identifiers | MRN HR-ML051-SYN-TD; SSN (made up) 000-51-2976 |
| Document date | 1971-06-15 |
| Author | Marisol Fairweather-Diaz, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week review: biopsy and staging results; medical oncology seen today. [S]
Mr. Neruda returns two weeks after his first visit, with a professional Spanish interpreter. In the past ten days he had an MRI of the prostate, a targeted biopsy at the urology practice, a CT scan, a bone scan and a PSMA PET/CT. The results were explained to him this morning by Dr. Okonkwo-Lund of medical oncology and again today: prostate cancer, Gleason 4+4, that has spread to two lymph nodes in the pelvis and to two places in the bones, the right hip bone and the lowest lumbar vertebra, with nothing in the lungs, liver or other organs. He chose, after hearing the options, to start apalutamide today, with a leuprolide injection in one week and radiotherapy to the prostate in about six weeks. His blood was drawn today for germline genetic testing after counseling. He had his bone density scan this morning. The right hip pain is a little better on acetaminophen, 5 of 10 at worst, and still wakes him some nights; he has no leg weakness, numbness, or change in bladder or bowel control. His urinary symptoms are unchanged. He feels the news is hard but says he would rather know. He wants to keep writing every morning and to continue his duties. [S]
| Element | Detail |
|---|---|
| Diagnosis | Prostate adenocarcinoma, Gleason 4+4 (Grade Group 4), 9 of 14 cores |
| Staging | Two pelvic lymph nodes and two bone metastases (right ilium, L5); no visceral disease: low volume |
| Decision | Apalutamide from today, leuprolide in one week, radiotherapy to the prostate; no docetaxel |
| Starting today | Apalutamide 240 mg daily; cholecalciferol 1945 units daily |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No weight loss, fever or night sweats |
| Genitourinary | Positive | Frequency, weak stream and nocturia three times, unchanged; no blood in the urine |
| Musculoskeletal | Positive | Right hip and low back pain, 5 of 10 at worst on acetaminophen |
| Neurological | Negative | No leg weakness, numbness or saddle numbness; no change in bladder or bowel control |
| Psychiatric | Negative | Worried but coping; PHQ-2 score 1 |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Amlodipine 5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1966-04-06 to 1971-07-13 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets (1000 mg) up to three times daily as needed for bone pain | Two tablets up to three times daily as needed | Oral route | 1971-06-01 to 1971-09-14 | completed | S |
| Apalutamide 240 mg oral tablet, one tablet once daily, swallowed whole, with or without food | One tablet once daily | Oral route | 1971-06-15 | active | S |
| Cholecalciferol (vitamin D3) 1945 units (0.05 mg) oral tablet, one tablet daily | One tablet daily | Oral route | 1971-06-15 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1971-06-15 | Body height | 178 | cm | S |
| 1971-06-15 | Body weight | 92 | kg | S |
| 1971-06-15 | Body mass index (BMI) [Ratio] | 29 | kg/m2 | S |
| 1971-06-15 | Systolic blood pressure | 142 | mm[Hg] | S |
| 1971-06-15 | Diastolic blood pressure | 86 | mm[Hg] | S |
| 1971-06-15 | Heart rate | 74 | /min | S |
| 1971-06-15 | Respiratory rate | 14 | /min | S |
| 1971-06-15 | Body temperature | 36.6 | Cel | S |
| 1971-06-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1971-06-15 | DXA Femur [T-score] Bone density | -2.1 | {T-score} | -1.0 or higher is normal; -2.5 or lower is osteoporosis | Low | S |
| 1971-06-15 | DXA Lumbar spine [T-score] Bone density | -1.4 | {T-score} | -1.0 or higher is normal; -2.5 or lower is osteoporosis | Low | S |
| 1971-06-15 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 1971-06-15 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 5 | {score} | S |
Vital signs recorded on 1971-06-15; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; walks without help, favoring the right hip slightly |
| Cardiovascular | Regular rhythm; blood pressure 142/86 mm Hg; no ankle swelling |
| Musculoskeletal | Tender over the right iliac crest; no midline spinal tenderness |
| Neurological | Strength 5 of 5 in both legs; sensation and knee and ankle reflexes normal |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Urinary frequency, weak stream and nocturia for four months, with right hip and low back pain for six weeks, a hard nodular prostate and a raised PSA; suspected prostate cancer, to be confirmed | resolved | confirmed | R97.20 | S — Synthetic presenting problem, resolved at the second visit when biopsy and staging established metastatic prostate cancer. |
| Adenocarcinoma of the prostate, Grade Group 4 (Gleason 4+4), cT3a N1 M1b, de novo metastatic hormone-sensitive disease, low volume by conventional imaging (two bone metastases, in the right ilium and L5, and two pelvic lymph nodes; no visceral disease); synthetic modern detail linked to his documented prostate cancer of 1916 | active | confirmed | C61 | S — Synthetic grade, stage, extent and PSA; the prostate cancer and the operation in France in 1971 are documented (D), and no stage, grade or treatment detail was found in the sources read. |
| Bone metastases from prostate cancer: right iliac wing (painful) and L5 vertebral body; no cord compression | active | confirmed | C79.51 | S — Synthetic metastatic sites. |
| Pelvic lymph node metastases: right external iliac and right obturator nodes | active | confirmed | C77.5 | S — Synthetic nodal disease. |
| Hormone-sensitive prostate cancer | active | confirmed | Z19.1 | S — Synthetic status in the modern episode. |
| Continuous androgen deprivation (leuprolide) with apalutamide, with monitoring of testosterone, PSA, thyroid function, blood pressure, glucose and lipids, bone health, rash, falls, hot flashes, sexual health, mood and cognition | active | confirmed | Z79.899 | S — Synthetic treatment plan; Z79.899 is used because ICD-10-CM has no specific code for GnRH agonist therapy. |
| Essential hypertension for five years, on amlodipine | active | confirmed | I10 | S — Synthetic comorbidity, relevant to cardiovascular risk on androgen deprivation; not a claim about his real blood pressure. |
| Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL) | active | confirmed | E55.9 | S — Synthetic finding at intake, addressed at the second visit. |
| Low bone mass (femoral neck T-score -2.1, L1 to L4 -1.4) with a ten-year hip fracture risk above 3% (FRAX, with androgen deprivation counted as a cause of secondary osteoporosis) | active | confirmed | M85.89 | S — Synthetic bone-health finding on the DXA before androgen deprivation. |
| Prediabetes (hemoglobin A1c 5.9%) | active | confirmed | R73.03 | S — Synthetic metabolic finding at intake, relevant to androgen deprivation. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | PSA before treatment | Baseline, then every 3 to 6 months on androgen deprivation | Up to date | 46.8 ng/mL at the first visit |
| Laboratory | Testosterone | Baseline, then every 3 to 6 months on androgen deprivation (target below 50 ng/dL) | Up to date | 468 ng/dL at the first visit |
| Laboratory | Blood count, chemistry, alkaline phosphatase and LDH | Baseline in metastatic disease | Up to date | Hemoglobin 13.6 g/dL; creatinine 0.96 mg/dL; alkaline phosphatase 168 U/L (raised); LDH 208 U/L; calcium 9.6 mg/dL |
| Laboratory | TSH before apalutamide | Baseline, then periodically on apalutamide | Ordered | Ordered today before the first dose |
| Laboratory | Hemoglobin A1c and lipid panel | Baseline and yearly on androgen deprivation | Up to date | A1c 5.9 percent and LDL 140 mg/dL at the first visit |
| Laboratory | Calcium and 25-hydroxyvitamin D | Baseline and periodically on androgen deprivation and bone-protective drugs | Up to date | Calcium 9.6 mg/dL and vitamin D 22 ng/mL at the first visit; cholecalciferol starts today |
| Imaging | Bone density (DXA) with FRAX | Baseline before androgen deprivation, then every 1 to 2 years | Completed today | Femoral neck T-score -2.1; L1 to L4 -1.4; FRAX hip 3.4 percent, major osteoporotic 13 percent |
| Imaging | Staging: CT, bone scan and PSMA PET/CT | At diagnosis | Up to date | Completed in the past ten days; low volume on conventional imaging; PSMA PET/CT concordant |
| Examination | Blood pressure and cardiovascular assessment | Every visit on androgen deprivation | Completed today | 142/86 mm Hg; no chest pain or breathlessness |
| Examination | Neurological check for spinal cord compression | Every visit with spinal metastases | Completed today | Normal leg strength, sensation and reflexes; no bladder or bowel change |
| Survey | Distress and depression screen (PHQ-2) | At diagnosis and at intervals | Completed today | PHQ-2 score 1 |
| Survey | Pain score | Every visit with symptomatic metastases | Completed today | 5 of 10 at worst on acetaminophen, down from 6 |
| Survey | Urinary symptoms (IPSS) | Baseline before treatment, then every follow-up visit | Up to date | IPSS 17 at the first visit; unchanged |
| Survey | Sexual function | Baseline before treatment and periodically | Completed today | Reviewed before androgen deprivation; loss of libido and erections explained |
| Survey | Cognition | Periodically on androgen deprivation | Due | Mini-Cog at the annual wellness visit |
| Medication safety | Testosterone flare protection | When starting a GnRH agonist with bone metastases | Completed today | Apalutamide starts today, one week before leuprolide |
| Medication safety | Drug interactions with apalutamide | When starting and with any new medicine | Completed today | Strong CYP3A4 inducer: amlodipine levels expected to fall; blood pressure check in four weeks |
| Medication safety | Falls and fracture risk on apalutamide | Every visit on androgen deprivation | Completed today | No falls; counseled on rugs, lighting and night-time walking |
| Referral | Medical oncology (genitourinary) | Once, then through treatment | Completed today | Seen today; recommendations in the consultation note |
| Referral | Germline genetic testing with counseling | Once, for metastatic disease | Completed today | Counseled and blood drawn today; result in two to three weeks |
| Referral | Radiation oncology for radiotherapy to the prostate | Once | Ordered | Planning visit in about four weeks |
| Self-management | Physical activity, calcium intake, no tobacco, and care in Spanish | Every visit | Completed today | Walking as pain allows; calcium from food; written plan in Spanish |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026); Advanced Prostate Cancer: AUA/SUO Guideline, first published 2020 and amended 2023 and 2026 (2026); ERLEADA (apalutamide) tablets: prescribing information (2026); CMID: Clinical Monitoring Intelligence Database, prostate cancer and hypertension monographs (2026)
Follow-up: Leuprolide at the oncology clinic in one week. Dental examination before the next visit. Review in four weeks with PSA, testosterone, chemistry, vitamin D and blood pressure. Next scheduled visit 1971-07-13: four-week review on apalutamide and leuprolide: early PSA response, testosterone, blood pressure, pain, the dental check and the first denosumab dose, and the radiotherapy plan. [S]